Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: A randomized controlled trial  by Koppensteiner, Renate et al.
Low-molecular-weight heparin for prevention of
restenosis after femoropopliteal percutaneous
transluminal angioplasty: A randomized
controlled trial
Renate Koppensteiner, MD,a Silviana Spring, MD,a Béatrice R. Amann-Vesti, MD,a Thomas Meier, MD,a
Thomas Pfammatter, MD,b Valentin Rousson, PhD,c Martin Banyai, MD,a and Bernd van der Loo, MD,a
Zurich, Switzerland
Background: Restenosis after angioplasty is essentially due to intimal hyperplasia. Low-molecular-weight heparins
(LMWHs) have experimentally been shown to have antiproliferative effects in addition to their antithrombotic
properties. Their potential in reducing restenosis remains to be established. Therefore, we wanted to test the hypothesis
that LMWH plus aspirin is more effective than aspirin alone in reducing the incidence of restenosis/reocclusion in
patients undergoing percutaneous transluminal angioplasty (PTA) of femoropopliteal arteries. Further, different effects
of LMWH in patients treated for critical limb ischemia (CLI) or claudication only should be investigated.
Methods: After successful PTA, 275 patients with symptomatic peripheral arterial disease (claudication or critical limb
ischemia) and femoropopliteal obstructions were randomized to receive either 2500 IU of dalteparin subcutaneously for
3 months plus 100 mg of aspirin daily (n  137), or 100 mg aspirin daily alone (n  138). The primary end point was
restenosis or reocclusion documented by duplex ultrasonography imaging at 12 months.
Results: Restenosis/reocclusion occurred in 58 patients (44%) in the dalteparin group and in 62 patients (50%) in the
control group (P  .30). In a subgroup analysis according to the severity of peripheral arterial disease, we found that in
patients treated for claudication, restenosis/reocclusion developed in 43 (43%) in the dalteparin group, and in 35 (41%)
in the control group (P .70); in patients treated for CLI, restenosis/reocclusion was significantly lower in the dalteparin
group (15, 45%) than in the control group (27, 72%; P  .01). No major bleeding events occurred in either group.
Conclusions: Treatment with 2500 IU dalteparin subcutaneously given for 3 months after femoropopliteal PTA failed to
reduce restenosis/reocclusion at 12 months. However, dalteparin may be beneficial in the subgroup of patients with CLI
at 12 months follow-up. (J Vasc Surg 2006;44:1247-53.)Restenosis is a major problem after initially successful
angioplasty of peripheral arteries and occurs in 35% to 50%
of noniliac peripheral angioplasties 1 year after the pro-
cedure.1,2 Causing necessity for further intervention, reste-
nosis has not only clinical but also economic implications.
Today, antiplatelet drugs are the treatment of choice for
secondary prevention in patients with arterial occlusive
disease. Aspirin or aspirin plus dipyridamole has been
shown to reduce the risk of vascular occlusion after vascular
procedures, especially in patients at high risk3; further,
antiplatelet therapy leads to a 25% reduction in vascular
events, including myocardial infarction, stroke, and vascu-
lar death.3 Aspirin is therefore given routinely to patients
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Restenosis is most commonly secondary to myointimal
proliferation. Lesions have been related to residual hemo-
dynamic abnormalities at the site of angioplasty, smooth
muscle cell injury, and platelet deposition with subsequent
release of platelet-derived growth factor. Experimental
studies suggest that the process of cellular proliferation
peaks 3 to 5 days after percutaneous transluminal angio-
plasty (PTA).4 Several pharmacologic and nonpharmaco-
logic approaches have been undertaken to improve the
results of catheter-based treatment, but a breakthrough has
not been achieved so far.
Low-molecular-weight heparins (LMWH) have been
shown in experimental studies to have antiproliferative
effects in addition to their antithrombotic properties,5 and
they have also been effective in a clinical setting. In a
randomized clinical trial in patients with femoropopliteal
bypass grafts, the effect of LMWH on graft patency was
compared with that of aspirin and dipyridamole. Graft
survival at 1 year was significantly higher in patients given
LMWH, and in particular, in patients receiving femoropop-
liteal grafts for limb salvage.6
The aim of this controlled, prospective, randomized
trial was to test the hypothesis that LMWH ismore effective
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patients undergoing PTA of femoropopliteal arteries. A
further question of interest was to investigate effects of
LMWH in patients treated for critical ischemia or claudica-
tion.
METHODS
Patients. From January 1999 to December 2004,
symptomatic patients with angiographically or sonographi-
cally documented femoropopliteal50% de novo or recur-
rent lesions scheduled for an interventional procedure at
the Division of Angiology, University Hospital Zurich,
were candidates for inclusion in the study. They were
eligible if femoropopliteal angioplasty (balloon angioplasty
with or without local thrombolysis and/or thrombus ex-
traction) was primarily successful.
Exclusion criteria were nonatherosclerotic vascular dis-
ease, lesions in femoropopliteal bypass grafts, stent implan-
tation, heparin or aspirin intolerance, anticoagulant treat-
ment before PTA, pregnancy, life expectancy12 months,
stroke, surgery of the eye or of the central nervous system
6months, proliferative diabetic retinopathy, active bleed-
ing, hemorrhagic diathesis, renal failure, uncontrolled
arterial hypertension, and unwillingness to return for
follow-up.
The study was conducted in accordance with the rec-
ommendations of the Declaration of Helsinki and was
approved by the local ethics committee. All patients gave
written informed consent. Patients were consented the day
after successful PTA and randomized immediately.
Recorded at baseline were age, sex, vascular risk factors
of diabetes, hyperlipidemia, hypertension, and smoking
habits; and history and current medication. The severity of
the peripheral arterial disease (PAD) was classified accord-
ing to Fontaine clinical stage II (claudication) or stage
III/IV (rest pain and/or nonhealing ulceration/gan-
grene).7
The initial clinical examination included palpation of
pulses, auscultation of bruits, pulse volume recordings,
ankle systolic pressure measurement, and calculation of
ankle-brachial index (ABI) at rest. Characteristics of the
lesions to be treated, as detected by angiography, were
recorded (stenosis/occlusion, length of lesion, run-off)
and classified according to the TransAtlantic InterSocietal
Consensus (TASC) classification.7
Laboratory tests included complete blood cell count
and levels of serum creatinine, fibrinogen, glycosylated
hemoglobin, cholesterol (high-density and low-density li-
poprotein), and triglycerides.
Trial design and treatment. The trial design was a
parallel group design, and patients were block randomized
to one of two treatment arms. The randomization code was
developed by using a computer random-number generator
to select random permuted blocks.
Basic treatment was 100 mg of aspirin per day, starting
the day before the procedure if the patient was not already
taking aspirin. After a successful interventional procedure,
the LMWH dalteparin (Fragmin, Pharmacia-Upjohn, Pfizer,NewYork,NY)was given in a subcutaneous dosage of 5000
IU once daily postoperatively for 2 days. Patients were
randomized to receive thereafter, for the next 3 months,
either 2500 IU dalteparin subcutaneously daily together
with 100mg aspirin orally or 100mg of aspirin orally alone.
Patients randomized to receive LMWH were instructed by
a nurse in the method of self-injection. A dosage of 2500
IU of dalteparin daily given for 3months has been shown to
be safe, without causing major hemorrhagic events.5
Follow-up and end points. Patients were assessed the
first day after the procedure and at 1, 3, 6, and 12 months
by taking a history, a clinical examination (palpation of
peripheral pulses, auscultation of bruits), pulse volume
recordings, ankle-systolic pressure measurements, calcula-
tion of ABI, and color-coded duplex ultrasound imaging of
the femoropopliteal segment. Peak systolic velocities (PSV)
in the dilated segment and in the proximal normal segment
were measured, and peak velocity ratio (calculated as PSV
in the dilated segment divided by proximally recorded PSV)
was calculated. A velocity ratio of 2.4 indicated a 50%
restenosis at that site.8 To retrieve the initially treated lesion
in follow-up duplex examinations, the lesions were mea-
sured in centimeters from the femoral bifurcation. All
sonographers were experienced investigators. They were
blinded to the group assessment.
Patients were also asked to return at any time during
follow-up in case of recurrence or worsening of symptoms.
The primary outcome measure was the occurrence of
restenosis 50% or reocclusion as documented by duplex
ultrasonography imaging (velocity ratio) at up to 12
months. Secondary outcome measures were clinical out-
come defined as recurrence or worsening of clinical symp-
toms, defined as deterioration by at least one category as
suggested by Rutherford,9 and deterioration of ABI de-
fined as decrease by 0.1.7
Compliance of the patients was assessed by observation
of the injection site and return of medication boxes. Side
effects of treatment, including bleeding or other adverse
events, were recorded.
Sample size calculation and statistical analysis. For
a predicted patency rate of 60% within the first year after
PTA, with a 15% difference between the two treatment
groups, the sample size required in each group was 138
patients to find this difference with 80% power and statis-
tical significance at the 5% level.
For data management and analyses, the statistical soft-
ware package Statview 5.0 (SAS Institute, Cary, NC) was
used. Continuous variables are reported as means  SD,
and categoric variables as counts or percentages. Compar-
isons between the two treatment groups were made by the
Mann Whitney U test for continuous variables and the 2
test for categoric variables. For the assessment of the out-
come, the 2 test was applied. Freedom from restenosis/
reocclusion according to treatment groups was plotted as
Kaplan-Meier curves and differences among groups were
analyzed by the log-rank test. Multivariate Cox propor-
tional hazard analysis (stepwise backward) was used to
study the association between restenosis/reocclusion and
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TASC class, run-off, diabetes, smoking, hyperlipidemia,
hypertension, and serum creatinine, expressing the results
as the hazard ratio (HR) with 95% confidence interval (CI).
A value of P  .05 was considered to indicate statistical
significance, and all tests were two-sided.
RESULTS
Patients. A total of 275 patients were recruited from
January 1999 to December 2004. The flow of participants
through each stage of the study is shown in Fig 1. A total of
255 patients completed the study protocol up to 12
months. The time of follow-up was 8.6  4 months in the
control group and 8.6 4 months in the dalteparin group
(P  .98).
From the 20 patients who did not complete follow-up,
one patient was considered a protocol violator (dalteparin
was terminated after 2 weeks) and 19 (7%) were lost to
follow-up (8 at 1 month, 4 at 3 months, 2 at 6 months, and
5 at 12 months). Of those, 10 patients died from myocar-
dial infarction, one from stroke, and one each from malig-
nant disease and venous thromboembolism. No informa-
tion could be obtained in six patients.
Baseline characteristics. Baseline demographic and
clinical characteristics as well as laboratory variables were sim-
ilar in both treatment groups (Table I and II). The groups
were also similar with respect to concomitant medication,
including statins, -blockers, angiotensin-converting in-
hibitors, angiotensin receptor blockers, oral antidiabetic
agents, insulin, and diuretic agents (all P  .05).
The indication for PTA was claudication in 196 pa-
tients and critical leg ischemia (CLI), defined as rest pain or
nonhealing ulcer, or both, in 79 patients. These two patient
subgroups, according to severity of PAD, were different
with respect to female gender and diabetes, which were
both more frequent in the CLI group (Table III).
Smokers were more frequent in patients with claudica-
Fig 1. Flow of patients through each stage of the study.tion. Lesion length was longer in patients with CLI, andthose patients were also more likely to have occlusions than
stenoses and 0-1 vessel run-off.
Follow-up and outcome. Restenosis/reocclusion de-
veloped in 62 patients in the control group and in 58
patients in the dalteparin group during the 12-month
follow-up, representing 50% and 44%, respectively (P 
Table I. Baseline characteristics of the two treatment
groups
Characteristic*
Control
group
n  138 (%)
Dalteparin
group
n  137 (%) P
Age (years) 70.2  11 69.9  10 .62
Male 60 56 .46
Diabetes 32 30 .69
Hypercholesterolemia 61 63 .70
Arterial hypertension 78 77 .88
Smoker 64 70 .24
History of coronary heart
disease 42 39 .71
History of cerebrovascular
disease 18 15 .62
Fontaine classification
II 67 75 .18
III/IV 32 24
Mean lesion length (cm) 7.8  8 6.1  7 .15
Total occlusion 42.7 43.4 .99
Run-off
0-1 vessel 38 30 .16
2-3 vessel 62 70
TASC classification
A 15 19 .57
B 33 34
C 38 37
D 14 10
Recurrent lesions 36 30 .34
Ankle-brachial index 0.70  0.18 0.66  0.18 .06
Velocity ratio† 5.4  1.6 5.6  1.6 .24
Velocity ratio 1 day after
PTA 1.24  0.41 1.22  0.41 .75
TASC, TransAtlantic InterSocietal Consensus; PTA, Percutaneous translu-
minal angioplasty.
*Data are shown as means  SD or as a percentage.
†Obtained in patients with stenoses only.
Table II. Baseline laboratory values of each group
Value
Control group
(n  138)
Dalteparin
group
(n  137) P
Creatinine (mol/L) 96.8  29 96.1  23 .89
Total cholesterol (mmol/L) 5.40  1.3 5.45  1.1 .55
HDL cholesterol (mmol/L) 1.46  0.43 1.41  0.42 .29
LDL cholesterol (mmol/L) 3.56  1.1 3.67  1.0 .25
Triglycerides (mmol/L) 1.80  1.0 1.86  1.1 .58
Glycosylated hemoglobin 0.074  0.01 0.079  0.01 .28
Hematocrit (%) 39.6  4.1 39.6  4.2 .61
Leukocytes (103/l) 8.00  2.0 8.1  2.7 .80
Platelets (103/l) 268  96 262  74 .79
Plasma fibrinogen (g/L) 3.76  0.77 3.79  0.98 .92
HDL, High-density lipoprotein; LDL, low-density lipoprotein..30; Fig 2, A).
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showed that in patients with CLI, the rate of restenosis/
reocclusion was higher in the control group than in the
dalteparin group (27 [73%] vs 15 [45%], P .01), whereas
no difference was seen in patients treated for claudication
(35 [41%] vs 43 [43%], P  .70; Fig 2, B and C).
Rates of restenosis/reocclusion by TASC classification
(A, B, C, D) were 38%, 35%, 42%, and 75% in the control
group (P  .03), and 20%, 32%, 64%, and 41% in the
dalteparin group (P  .0008).
Velocity ratio according to treatment groups in all
patients and in the subgroup of CLI patients is shown in
Fig 3, A. In CLI patients, velocity ratio was significantly
higher in the control group than in the dalteparin group at
6 months and at 12 months (P  .01 each; Fig 3, B).
The relative incidence (cumulative) of restenosis vs
rethrombosis at 12 months was 61% vs 39% in the control
group and 79 vs 21% in the treatment group (P  .03).
PTA resulted in an increase in ABI from 0.7  0.18 to
0.87  0.16 (P  .0001) in the control group, and from
0.66  0.18 to 0.89  0.16 (P  .0001) in the dalteparin
group. At 1, 3, and 12 months, ABI values were 0.88 
0.16, 0.86  0.17, and 0.82  0.19 in the control group,
and 0.90  0.16, 0.88  0.16, and 0.88  0.15 in the
dalteparin group.
From a total of 120 patients with restenosis/reocclu-
sion demonstrated by duplex ultrasonographic imaging,
102 (85%) presented with a drop 0.1 in ABI, and 89
(74%) had recurrence or worsening of clinical symptoms.
Post-hoc subgroup analysis according to the severity of
Table III. Baseline characteristics of patients treated for
claudication and critical limb ischemia
Characteristic*
Claudication
n  196 (%)
CLI
n  79 (%) P
Dalteparin/Control
group 47/53 56/44 .18
Age (years) 69.7  10 70.8  11 .34
Male 64 44 .002
Diabetes 25 46 .001
Hypercholesterolemia 63 57 .33
Arterial hypertension 78 77 .99
Smoker 73 53 .002
Mean lesion length (cm) 6.1  6 8.9  9 .01
Total occlusion 35 62 .0001
Run-off
0-1 vessel 28 45 .01
2-3 vessel 72 55
TASC
A 20 10 .059
B 34 31
C 37 41
D 9 18
Recurrent lesions 37 33 .56
Ankle-brachial index 0.73  0.16 0.49  0.14 .0001
TASC, TransAtlantic Intersociety Classification; PTA, percutaneous Trans-
luminal Angioplasty.
*Data are percentages, and means  SD.PAD showed that in patients treated for CLI, recurrence orworsening of symptoms and drop in ABI were less frequent
in the dalteparin group than in the control group: recur-
rence/worsening of clinical symptoms, 11 (33%) vs. 22
(59%) (P .02); drop in ABI 0.1, 12 (37%) vs 23 (62%)
(P  .04).
Cox proportional hazards model. An interaction
term between the treatment factors (dalteparin/control)
and severity of PAD (claudication/CLI) was included into
a Cox regression model and was found significant (P 
.02). This meant that the effect of the treatment was
Fig 2. A, Kaplan-Meier curve for freedom from restenosis/reoc-
clusion by treatment group (total). B, Kaplan-Meier curve for
freedom from restenosis/reocclusion in patients with claudication
by treatment group. C, Kaplan-Meier curve for freedom from
restenosis/reocclusion in patients with critical limb ischemia by
treatment group.significantly different for patients with claudication and
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tion and CLI separately. It was found that lack of treatment
with dalteparin, presence of diabetes, lesion length, and
renal creatinine were associated with restenosis in patients
with CLI. With a hazard ratio of 3.95, diabetes was the
strongest single predictor of restenosis in CLI patients. In
patients with claudication, however, lesion length and le-
sion morphology according to TASC were the only signif-
icant predictors for the development of restenosis/reocclu-
sion (Table IV).
Adverse events. Special attention was paid to the oc-
currence of heparin-induced thrombocytopenia,10 but nei-
ther this nor major bleeding events were observed in either
group. Injection-site bruising was seen in seven patients
(5.3%) in the dalteparin group; and as result, one of these
patients discontinued the dalteparin medication.
Platelet count and hematocrit were not different be-
tween the control group and the dalteparin group at any
point of time during follow-up. Platelets values at baseline
were 266 99 vs 265 77; 1 day postintervention, 250
100 vs 254  74; 1 month, 236  75 vs 259  88; 3
months, 241 101 vs. 251 66; 6 months, 236 104 vs
249  75; and 12 months, 242  78 vs 240  69.
Hematocrit values at baseline were 39.7 4 vs 39.5 4; 1
day, 39.0  4 vs 39.0  4; 1 month, 36.4  4 vs 37.5 
3.3; 3 months, 38.5 4 vs 38.7 4; 6 months, 37.7 3.7
vs 37.4  4; and 12 months, 36.9  4 vs 38.4  4 (all
Fig 3. A, Peak velocity ratio (Vr) after femoropopliteal percuta-
neous transluminal angioplasty (PTA) in the total of patients by
treatment group. B, Peak velocity ratio (Vr) after femoropopliteal
PTA in patients with critical limb ischemia by treatment group.
Boxes show medians (25th to 75th percentile); the blue dots
represent all observations10th or90th percentile, respectively.P  .05).DISCUSSION
Our study demonstrates that a regimen of 2500 IU of
dalteparin administered subcutaneously daily for 3 months
in addition to standard therapy with aspirin at 100 mg/d,
compared with aspirin alone, offers no significant benefit
for the entire cohort of patients with symptomatic PAD
treated with femoropopliteal PTA. In a subgroup analysis,
however, we observed a significant effect in reducing the
rate of restenosis/reocclusion in patients with CLI at 12
months follow-up. In this subgroup, lack of treatment with
dalteparin and the presence of diabetes were the most
powerful predictors of restenosis/reocclusion, whereas in
patients with claudication only, lesion morphology (ac-
cording to TASC classification and lesion length) remained
significant in the multivariate analysis. Therefore, patients
with claudication did not seem to have an additional benefit
from administration of LMWH compared with standard
therapy alone.
To date, there are only few data about the effect of
LMWH on restenosis after interventional procedures of
peripheral arteries. In a pilot study of 42 patients,11 revipa-
rin (3500 IU), another LMWH, given twice a day for 23
days reduced the incidence of restenosis after stent implan-
tation due to primarily unsuccessful PTA of the femoro-
popliteal segment. Furthermore, a beneficial effect of the
LMWH nadroparin was suggested in patients with exten-
sive dissection after PTA in the iliac or superficial femoral
artery.12
To the best of our knowledge, however, ours was the
first randomized and prospective study to investigate the
effect of low-dose LMWH on the reduction of restenosis/
reocclusion after primarily successful femoropopliteal PTA,
which is by far the most often interventional procedure
performed in patients with PAD.
Several trials have investigated the effect of LMWH on
the incidence of restenosis after percutaneous transluminal
coronary angioplasty (PTCA).13-15 In two of those tri-
als,13,14 LMWH was also given for 3 months after PTCA,
Table IV. Multivariate Cox proportional hazards analysis*
HR 95% CI P
Claudication
Lesion length 1.104 1.05-1.16 .0001
TASC 0.02
1 1 — —
2 3.45 0.92-12.9 .06
3 5.60 1.39-22.4 .01
4 5.72 1.75-18.7 .0039
Critical limb ischemia
Treatment group 2.74 1.23-6.0 .01
Diabetes 3.95 1.6-9.7 .002
Lesion length 1.04 1.00-1.08 .01
Creatinine 0.97 0.95-0.99 .02
HR, Hazard ratio; CI, confidence interval; TASC, TransAtlantic Intersoci-
ety Classification.
*Stepwise backward.either in a low-dose or a high-dose scheme. In the Reduc-
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Reviparin in a Double-Blind Unfractionated Heparin and
Placebo-Controlled Evaluation (REDUCE) trial,15 3500
IU of reviparin was only administered for 28 days. No effect
on the incidence of restenosis was observed. The diver-
gence in our results in the peripheral arteries compared with
the results in the coronary arteries may be explained by
heterogeneity of the vasculature and by differences in the
pathophysiologic mechanisms underlying restenosis in the
coronary vs the femoropopliteal arteries.
According to the response-to-injury hypothesis,16 re-
stenosis is caused by intimal hyperplasia due to proliferation
and migration of smooth muscle cells from the media into
the intima. LMWH may inhibit proliferation and intimal
hyperplasia.5,17
Another possible pathophysiologic explanation for our
findings might be the anti-inflammatory effects of LMWH, 18
including its inhibitory effect on cytokines and cytokine-
mediated chemotaxis19 and on monocyte adhesion to endo-
thelial cells.20 This pleiotropic effect of LMWH, independent
of its anticoagulatory effect, that modulates the inflamma-
tory response, may possibly at least partly explain its benefit
in patients with CLI compared with patients with claudica-
tion only. Cytokine expression in skeletal muscle has re-
cently been associated with experimentally induced limb
ischemia–reperfusion injury.21 Furthermore, the important
role of inflammation in CLI been underlined by a report
showing a link between low levels of inflammatory indica-
tors and survival rate in those patients.22
Of interest is that our data are virtually in complete
agreement with previously published data on the effect of
LMWH given for 3 months in patients undergoing femo-
ropopliteal bypass grafting.6 Comparable with the results of
our study, the benefit of LMWH in this former study was
confined to those patients undergoing surgery for CLI
(“salvage surgery”). There was no significant benefit for
those who had surgery for claudication. Furthermore, also
in agreement with our data (see Fig 2, C), the benefit of
LMWH in patients undergoing salvage surgery started to
become evident at 3 months and was accentuated at 6 and
12 months after surgery. Obviously, the fact that CLI
patients undergoing femoropopliteal PTA started to have a
significant benefit from LMWH treatment 3 months after
stopping therapy cannot be explained on the basis of better
antithrombotic properties of LMWH. As outlined, how-
ever, both the antiproliferative and the anti-inflammatory
effects of LMWH may be causally involved.
This therapy could represent an advance in the treat-
ment of patients with peripheral vascular disease, particu-
larly those with CLI. It still remains unclear, however, why
LMWHs reduce restenosis/reocclusion in patients with
CLI but do not provide a similar benefit in patients with
claudication undergoing the same vascular procedure. A
difference in the rates of restenosis might have partly been
due to a difference in delayed thrombosis rates and may
possibly provide another explanation for the benefit of a
LMWH in patients with CLI. Further investigation isneeded in this area before this treatment may be imple-
mented into clinical practice.
Limitations. This prospective, randomized clinical
trial was conducted as a single-center study. Although this
does not necessarily imply a limitation by itself, we are
aware that in other centers, for example, major centers in
the United States, that practice may be different in that a
higher percentage of peripheral angioplasty may have been
performed with stenting. Our study was initiated in early
1999, when evidence for the use of (nitinol) stents, in
particular, for the treatment of high-risk lesions in the
femoropopliteal segment was still lacking. Given current
knowledge and practice, however, a stent would have been
implanted in more patients, in particular those with high-
risk lesions. This may imply that LMWHmight be of some
benefit when PTA alone is used to treat such lesions.
Furthermore, clopidogrel, which is now used in a wide-
spread fashion, was not examined in our study.
Another limitation is that for logistic reasons, this study
was not placebo-controlled; however, the presence of
restenosis/reocclusion was determined by ultrasonogra-
phers who were blinded with respect to the patients= treat-
ment group.
Finally, we are aware that our finding regarding the
positive effect of LMWH treatment in the subgroup of
patients with CLI is somewhat hypothesis-generating, as it
does not represent the true primary end point of this trial.
We are grateful to Roger Simon, MD, Susanne Banyai-
Falger, MD, Elisabeth Krieger-Alt, MD, and Tamara Ko-
vacevic, MD, for help with patient recruitment and data
collection. We are indebted to Theo Gasser, PhD, Head of
the Department of Biostatistics at the University of Zurich,
for help with designing the study.
AUTHOR CONTRIBUTIONS
Conception and design: RK
Analysis and interpretation: RK, SS, VR, BV
Data collection: SS, BA, TM, TP, MB, BV
Writing the article: RK, BV
Critical revision of the article: RK, SS, BA, TM, TP, VR,
MB, BV
Final approval of the article: RK, SS, BA, TM, TP, VR,
MB, BV
Statistical analysis: VR
Obtained funding: RK
Overall responsibility: RK
REFERENCES
1. Johnston KW, Rae M, Hogg-Johnston SA, Colapinto RF, Walker PM,
Baird RJ, et al. Five-year results of a prospective study of percutaneous
transluminal angioplasty. Ann Surg 1987;206:403-13.
2. Berkowitz HD, Spence RK, Freiman DB. Long-term results of translu-
minal angioplasty of the femoral arteries. In: Dotter CT, Grüntzig AR,
SchoopW, et al, editors. Percutaneous transluminal angioplasty, Berlin:
Springer Verlag; 1983. p. 207-14.
3. Antiplatelet Trialists Collaboration. Collaborative overview of random-
ised trials of antiplatelet therapy - II: Maintenance of vascular graft or
arterial patency by antiplatelet therapy. BMJ 1994;308:159-68.
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 6 Koppensteiner et al 12534. Wilensky RL, March KL, Gradus-Pizlu I, Sandusky G, Fineberg N,
Hathaway DR. Vascular injury, repair, and restenosis after percutaneous
transluminal angioplasty in the atherosclerotic rabbit. Circulation 1995;
92:2995-3005.
5. Wilson NV, Salisbury JR, Kakkar VV. Effect of low molecular weight
heparin on myointimal hyperplasia. Brit J Surg 1991;78:1381-3.
6. Edmondson RA, Cohen AT, Das SK, Wagner MB, Kakkar VV. Low-
molecular weight heparin versus aspirin and dipyridamole after femoro-
popliteal bypass grafting. Lancet 1994;344:914-8.
7. Dormandy JA, Rutherford RB. Management of peripheralarterial dis-
ease (PAD). Transatlantic InterSociety Consensus (TASC). J Vasc Surg
2000;31:S1-296.
8. Ranke C, Creutzig A, Alexander K. Duplex scanning of peripheral
arteries: correlation of the peak velocity ratio with angiographic diam-
eter reduction. Ultrasound Med Biol 1992;18:433-40.
9. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S,
et al. Recommended standards for reporting dealing with lower ex-
tremity ischemia: revised version. J Vasc Surg 1997;26:517-38.
10. Warkentin Th, Levine M, Hirsh J, Horsewood P, Roberts RS, Gent M,
et al. Heparin-induced thrombocytopenia in patients treated with low
molecular weight heparin. N Engl J Med 1995;332:1330-5.
11. Strecker EP, Göttmann D, Boos I, Vetter S. Low-molecular-weight
heparin (reviparin) reduces the incidence of femoropopliteal in-stent
restenosis: preliminary results of an ongoing study. Cardiovasc Inter-
vent Radiol 1998;21:375-9.
12. Schweizer J, Müller A, Forkmann L, Hellner G, Kirch W. Potential use
of a low-molecular-weight heparin to prevent restenosis in patients with
extensive wall damage following peripheral angioplasty. Angiology
2001;52:659-69.
13. Gimple LW, Herrmann HC, Winniford M, Mammen E. Usefulness of
subcutaneous low molecular weight heparin (ardeparin) for reduction
of restenosis after percutaneous transluminal angioplasty. Am J Cardiol
1999;83:1524-9.
14. Lablanche JM, McFadden EP, Meneveau N, Lusson JR, Bertrand B,
Metzger JP, et al. Effect of nardoparin, a low-molecular-weight heparin,on clinical and angiographic restenosis after coronary balloon angio-
plasty: the FACT study. Fraxiparine Angioplastie Coronaire Translumi-
nale. Circulation 1997;96:3396-402.
15. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia
EJ, et al. Low molecular weight heparin (reviparin) in percutaneous
transluminal coronary angioplasty. Results of a randomized, double-
blind, unfractionated heparin and placebo-controlled, multicenter trial
(REDUCE trial). Reduction of restenosis after PTCA, early administra-
tion of reviparin in a double-blind unfractionated heparin and placebo-
controlled evaluation. J Am Coll Cardiol 1996;28:1437-43.
16. Ross R. The pathogenesis of atherosclerosis–an update. N Engl J Med
1986;314:488-500.
17. Ao PY, Hawthorne WJ, Coombs R, Fletcher JP. Suppression of intimal
hyperplasia with low molecular weight heparin in a sheep model. Int
Angiol 1999;18:131-9.
18. Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coro-
nary intervention in non ST-elevation acute coronary syndromes: the
role of modulating inflammation. Circulation 2003;108:III22-7.
19. Christopherson KW, Campbell JJ, Travers JB, Hromas RA. Low-
molecular weight heparins inhibit CCL21-induced T cell adhesion and
migration. J Pharmacol Exp Ther 2002;302:290-5.
20. Manduteanu I, Voinea M, Capraru M, Dragomir E, Simionescu M. A
novel attribute of enoxaparin: inhibition of monocyte adhesion to
endothelial cells by a mechanism involving cell adhesion molecules.
Pharmacology 2002;65:32-7.
21. Hua HT, Al-Badawi H, Entabi F, Stoner MC, Diamond RE, Bonheur
JA, et al. CXC chemokine expression and synthesis in skeletal muscle
durino ischemia/reperfusion. J Vasc Surg 2005;42:337-43.
22. Barani J, Nilsson JA, Mattiasson I, Lindblad B, Gottsater A. Inflamma-
tory mediators are associated with 1-year mortality in critical limb
ischemia. J Vasc Surg 2005;42:75-80.Submitted May 2, 2006; accepted Jul 26, 2006.
